Scholar Rock Holding Corporation (SRRK): Price and Financial Metrics
SRRK Price/Volume Stats
| Current price | $13.85 | 52-week high | $21.17 |
| Prev. close | $13.95 | 52-week low | $5.56 |
| Day low | $13.18 | Volume | 707,144 |
| Day high | $14.20 | Avg. volume | 781,112 |
| 50-day MA | $15.39 | Dividend yield | N/A |
| 200-day MA | $11.84 | Market Cap | 1.08B |
SRRK Stock Price Chart Interactive Chart >
Scholar Rock Holding Corporation (SRRK) Company Bio
Scholar Rock Holding Corporation discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was founded in 2012 and is based in Cambridge, Massachusetts.
Latest SRRK News From Around the Web
Below are the latest news stories about SCHOLAR ROCK HOLDING CORP that investors may wish to consider to help them evaluate SRRK as an investment opportunity.
Scholar Rock to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., December 19, 2023--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. PT (4:30 p.m. ET). |
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., December 15, 2023--Scholar Rock (NASDAQ: SRRK; "The Company"), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 78,576 shares of its common stock to 6 newly hired employees, consisting of inducement stock options to purchase an aggregate of 44,900 shares of common stock and inducement |
Insider Sell: COO & CFO Edward Myles Sells 24,914 Shares of Scholar Rock Holding Corp (SRRK)Edward Myles, the Chief Operating Officer and Chief Financial Officer of Scholar Rock Holding Corp (NASDAQ:SRRK), has recently sold 24,914 shares of the company's stock. |
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2023 Earnings Call TranscriptScholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2023 Earnings Call Transcript November 7, 2023 Rushmie Nofsinger: Good morning. I’m Rushmie Nofsinger, Vice President of Corporate Affairs and Investor Relations at Scholar Rock. Welcome, and thank you for joining us today for our Q3 2023 Business Update Call. This call is audio-only. You can access the slides […] |
Scholar Rock Holding Corp (SRRK) Reports Q3 2023 Financial ResultsCompany Completes $98 Million Public Offering, Extends Cash Runway into H2 2025 |
SRRK Price Returns
| 1-mo | -15.81% |
| 3-mo | -8.03% |
| 6-mo | 81.28% |
| 1-year | 92.09% |
| 3-year | -56.83% |
| 5-year | -20.54% |
| YTD | -26.33% |
| 2023 | 107.73% |
| 2022 | -63.57% |
| 2021 | -48.82% |
| 2020 | 268.21% |
| 2019 | -42.62% |
Continue Researching SRRK
Here are a few links from around the web to help you further your research on Scholar Rock Holding Corp's stock as an investment opportunity:Scholar Rock Holding Corp (SRRK) Stock Price | Nasdaq
Scholar Rock Holding Corp (SRRK) Stock Quote, History and News - Yahoo Finance
Scholar Rock Holding Corp (SRRK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...